At the registrar level, what should I know about the pathophysiology, pharmacologic classes, and management of dementia, including inpatient and outpatient monitoring?

Dementia: Essential Registrar-Level Knowledge

Pathophysiology

Dementia results from aggregation of misfolded proteins and cerebrovascular disease, with mixed neuropathologies being the rule rather than the exception in older adults 1.

Key Pathophysiological Mechanisms by Type:

• Alzheimer's Disease (50-70% of cases): Accumulation of amyloid-β plaques and neurofibrillary tangles (tau protein) leading to neuronal death and cholinergic deficiency 2, 1

• Vascular Dementia: Cerebrovascular disease causing white matter changes, lacunar infarctions, and strategic cortical infarcts 1

• Lewy Body Dementia: Alpha-synuclein aggregation forming Lewy bodies, with prominent cholinergic and dopaminergic deficits 1

• Frontotemporal Dementia: Tau or TDP-43 protein aggregation causing frontal and temporal lobe degeneration 1

Critical Point: Most elderly patients with dementia have mixed pathologies (AD + vascular + Lewy bodies), which has major treatment implications 1.

---

Pharmacologic Classes

Cholinesterase Inhibitors (First-Line for Mild-Moderate Dementia)

All three agents (donepezil, rivastigmine, galantamine) provide modest but statistically significant benefits, though average improvements often don't reach clinically significant thresholds 3.

Donepezil (Aricept)

• Dosing: Start 5 mg daily, increase to 10 mg after 4 weeks 4
• Administration: Once daily, any time 4
• Advantages: No hepatotoxicity, easiest dosing schedule 4
• Evidence: Statistically significant ADAS-cog improvement but typically <4 points (clinically significant threshold); 20-35% of patients show clinically meaningful response 3, 4

Rivastigmine (Exelon)

• Dosing: Oral 1.5 mg BID, titrate to 3-6 mg BID; Patch 4.6-13.3 mg/24h 4
• Special consideration: May offer additional benefit in rapid decliners and those with vascular risk factors 5
• Evidence: 3-point ADAS-cog improvement in meta-analysis 6

Galantamine (Reminyl)

• Dosing: Start 4 mg BID, titrate to 8-12 mg BID 4
• Mechanism: Dual action (cholinesterase inhibition + nicotinic receptor modulation) 4

Common Side Effects (All ChEIs)

• GI: Nausea (RR 2.54), diarrhea (RR 2.57), vomiting 3
• Cardiovascular: Bradycardia, syncope
• Neuropsychiatric: Insomnia, abnormal dreams
• Management: Gradual titration, take with food, adequate hydration 7

Memantine (For Moderate-Severe Dementia)

Memantine is recommended for moderate to severe dementia as monotherapy or combined with cholinesterase inhibitors 2.

• Mechanism: NMDA receptor antagonist, prevents glutamate excitotoxicity 6
• Dosing: Start 5 mg daily, titrate weekly by 5 mg to 10 mg BID (target 20 mg/day)
• Evidence: 1-3 point ADAS-cog improvement; combination with donepezil recommended for severe AD in most guidelines 6, 2

Combination Therapy

Memantine + donepezil is recommended for severe AD (recommended in US, China, Japan guidelines; UK is exception) 2.

---

Management Algorithm

Initial Assessment & Diagnosis

When cognitive impairment is suspected, perform structured cognitive testing using validated instruments, not just clinical impression 8.

1. Screening Tools:

   • MMSE: Sensitivity 88.3%, specificity 86.2% at 23/24 cutoff; ≥3-point change is clinically significant 3, 6
   • MoCA: Superior to MMSE for detecting MCI and mild AD 2
   • Clock Drawing Test, Mini-Cog: Brief alternatives 6

2. Comprehensive Evaluation Must Include:

   • Detailed history from patient AND informant (critical)
   • Assessment across 7 cognitive domains: memory, attention, executive function, language, visuospatial, praxis, social cognition 2
   • Functional assessment (ADLs/IADLs)
   • Behavioral/neuropsychiatric symptoms
   • Comorbidities (depression, delirium, medications with anticholinergic effects) 4

3. Laboratory Workup (to exclude reversible causes):

   • CBC, comprehensive metabolic panel
   • TSH, B12, folate
   • Consider: RPR, HIV (if risk factors), heavy metals, autoimmune panel

4. Neuroimaging: Brain MRI or CT to identify:

   • Vascular changes (white matter disease, lacunar infarcts)
   • Structural abnormalities
   • Exclude NPH, subdural hematoma, tumor 5

Urgent Referral Criteria

Refer immediately to specialist for 8, 9:

• Rapidly progressive dementia (weeks to months)
• Delirium (urgent/emergent)
• Early-onset dementia (age <65)
• Atypical presentations: Prominent aphasia, apraxia, agnosia, movement disorders, visual symptoms
• Fluctuating course suggesting Lewy body dementia
• Uncertainty in diagnosis after initial evaluation

Treatment Initiation

Set realistic expectations: medications provide modest symptomatic benefit (equivalent to 6-12 months delay in decline) in 20-35% of patients, not disease cure 4.

Mild-Moderate Dementia:

1. Start cholinesterase inhibitor (donepezil preferred for ease of use) 2
2. Add vitamin E 1000 IU BID (safe, low cost, may slow progression) 7
3. Consider rivastigmine specifically if:
   • Vascular risk factors present 5
   • Rapid decline (MMSE loss ≥3 points in 6 months) 5

Moderate-Severe Dementia:

1. Memantine as monotherapy OR
2. Memantine + donepezil combination (preferred) 2

Behavioral/Psychological Symptoms (BPSD)

Always attempt non-pharmacologic interventions first 4, 10, 11.

Non-pharmacologic strategies:

• Environmental modification (calm, predictable, safe)
• Remove stressors and triggers
• Redirect/refocus techniques
• Regular sleep schedule
• Structured activities (music therapy, reminiscence, physical exercise)
• Caregiver education and support 4, 11

Pharmacologic management (only after non-pharmacologic failure or severe harm risk) 10:

• Agitation/Aggression:

  • Citalopram 10-30 mg daily (first-line antidepressant) 12
  • Atypical antipsychotics (risperidone 0.5-2 mg) ONLY if severe or dangerous; use lowest dose, shortest duration 10, 12
  • Black box warning: Increased mortality risk with antipsychotics in elderly with dementia

• Depression: SSRIs (citalopram, sertraline) 12

• Psychosis in AD: Pimavanserin shows efficacy 12

• REM sleep behavior disorder in Lewy body: Cholinesterase inhibitors, memantine 12

---

Monitoring

Outpatient Monitoring

Establish regular, preplanned follow-up with minimum involvement of general practitioner and easy specialist access 10.

Every 3-6 Months (more frequent if rapid decline):

1. Cognitive Assessment:

   • Repeat MMSE or MoCA
   • Clinically significant decline: ≥4 points ADAS-cog, ≥3 points MMSE 3
   • CIBIC-plus (global impression with caregiver input) 3

2. Functional Assessment:

   • ADL/IADL scales
   • Bristol Activities of Daily Living Scale 3

3. Behavioral Assessment:

   • Neuropsychiatric Inventory 3
   • Screen for depression, psychosis, agitation

4. Medication Review:

   • Efficacy: If no benefit after 3-6 months trial at therapeutic dose, consider discontinuation
   • Tolerability: GI symptoms, bradycardia, weight loss
   • Eliminate anticholinergic medications (major cause of excess disability) 4

5. Vascular Risk Factor Management:

   • Aggressively control: Hypertension, diabetes, hyperlipidemia, atrial fibrillation 10
   • Anticoagulation for AF: Recommended in dementia without prior stroke 10

6. Caregiver Assessment:

   • Burden, depression, burnout
   • Need for respite care, support groups
   • Caregiver wellbeing directly impacts patient outcomes 4, 11

7. Safety Issues:

   • Driving capacity (state reporting requirements)
   • Wandering risk
   • Financial exploitation
   • Elder abuse screening 4

Inpatient Monitoring

Hospitalized dementia patients are at extremely high risk for delirium and functional decline.

Daily Assessment:

1. Delirium screening (Confusion Assessment Method)

2. Medication reconciliation: Discontinue/minimize:

   • Anticholinergics
   • Benzodiazepines
   • Opioids (assess risk-benefit daily; discontinue if no clear indication) 10
   • Antipsychotics (unless essential)

3. Maintain function:

   • Early mobilization
   • Orientation cues (clock, calendar, familiar objects)
   • Sleep-wake cycle preservation
   • Adequate nutrition/hydration

4. Pain assessment: Use observational scales (PAINAD) if patient cannot self-report 10

5. Avoid physical restraints (increase delirium, injury risk)

Rapid Decline Recognition

Rapid cognitive decline (RCD) = MMSE loss ≥3 points in 6 months or ≥5 points per year 5.

RCD occurs in 20% of mild dementia, 43% of moderate dementia 5.

Risk factors for RCD:

• MMSE <20 at treatment onset
• Vascular risk factors
• Early hallucinations/psychosis
• Extrapyramidal symptoms
• Higher education
• Age <70 at symptom onset 5

Management of RCD:

1. Rule out delirium, stroke, medication effects 5
2. Consider switching to rivastigmine (may offer benefit over donepezil in rapid decliners with vascular factors) 5
3. Repeat brain imaging (CT/MRI) to assess for new vascular events 5
4. Intensify vascular risk factor control 5
5. Increase follow-up frequency
6. Anticipate rapid loss of autonomy: Advance care planning, caregiver support 5

---

Critical Pitfalls to Avoid

1. Mistaking delirium for dementia progression: Always investigate acute changes (infection, medications, metabolic derangement) 4, 8

2. Polypharmacy with anticholinergics: Review ALL medications; many OTC drugs have anticholinergic effects 4

3. Premature antipsychotic use: Exhaust non-pharmacologic strategies first; antipsychotics increase mortality 10, 12

4. Ignoring caregiver burden: Caregiver breakdown is the #1 reason for institutionalization 4, 11

5. Unrealistic medication expectations: Counsel that drugs provide modest benefit (6-12 month delay), not cure 4

6. Missing atypical presentations: Young-onset, rapidly progressive, or atypical features require urgent specialist referral 8, 9

7. Neglecting vascular risk factors: These are modifiable and impact progression 5, 10

8. Continuing ineffective medications indefinitely: If no benefit after adequate trial, discontinue 10

9. Inadequate pain management: Untreated pain worsens behavioral symptoms; use observational scales 10

10. Failing to address end-of-life planning early: Discuss advance directives, goals of care while patient has capacity 4, 2